資源描述:
《肺腺樣囊性癌4例病例報告》由會員上傳分享,免費在線閱讀,更多相關內(nèi)容在工程資料-天天文庫。
1、肺腺樣囊性癌4例病例報告賀璽蘭陳建華中南大學湘雅醫(yī)學院中南大學湘雅醫(yī)學院附屬腫瘤醫(yī)院胸部內(nèi)一科摘要:背景與口的肺腺樣囊性癌是肺癌屮的少見類型,通常對其診斷及治療認識不足。為了提高對肺腺樣囊性癌的認識,本文對該病例進行了收集和分析。方法回顧分析我院2012年10-2016年12月收治的4例肺腺樣囊性癌,對其病理免疫組化、表皮生長因子受體(epidermalgrowthfactorreceptor,EGFR)及間變性淋巴瘤激酶(anaplastic1ymphomakinase,ALK)突變分析、診斷和治療特點進
2、行總結(jié)。結(jié)果肺腺樣囊性癌是一種主要發(fā)生在氣道、EGFR及ALK突變少見、轉(zhuǎn)移較晚、手術治療效果好的一種疾病。結(jié)論肺腺樣囊性癌診斷主要依賴于病理學,早期以手術治療為主,晚期可行放化療,但靶向治療機會不多,其預后較小細胞肺癌及非小細胞肺癌好。關鍵詞:肺腺樣囊性癌;肺腫瘤;診斷;治療;作者簡介:陳建華,E-ina訂:cjh_1000@163.com收稿日期:2017-08-26FourCasesReportonPrimaryLungAdenoidCysticCarcinomaX訂anHEJianhuaCHENXi
3、angyaSchoolofMedicineCentralSouthUniversity;DepartmentofThoracicNeoplasms,HunanCancerHospital,theAffliatedCancerHosoitalofXiangyaSchoolofMedicineCentralSouthUniversity;Abstract:BackgroundandobjectiveLungadenoidcysticcarcinomaisakindofrarelungcancer.Diagnos
4、isandtreatmentisnotenoughunderstandableforthem.Wecollectedandanalyzed4casesoflungadenoidcysticcarcinomaforbroadeningthesightofthisdisease.MethodsRetrospectivelyanalysedthe4caseswecollcctedfromIlunanCancorHospitalBetweenJanuary2012andDecember2016.Wedepicted
5、thepathology,immunohistochemical,epidermalgrowthfactorreceptor(EGFR)mutationandanaplasticlymphomakinase(ALK)arrangementinthesecases.Andthemethodsofthediagnosisandtreatmentwereanalyzed.ResuItsLungadenoidcysticcareinomaisusuallylocatedintheairway,EGFRmuteiti
6、onandALKarrangementisrareinthisdisease.Generallythemetastasisofthelungcanceroccurredintheadvancedstage.Theprognosisisgoodifthemasscouldberesectedcompletely.ConelusionDiagnosisofthelungadenoidcysticcarcinomadependsonpathologicalexperiments,surgeryisthemaint
7、reatmentintheceirlystage,radiotherapyandchcmotherapyisanadvisabletherapyintheadvancedstage.Andtheprognosisofthiskindoflungcancerisbetterthansmallcelllungcancerandnon-smallcelllungcancer.Keyword:Lungadenoidcysticcareinomet;Lungneoplasms;Diagnosis;Treatment;
8、Received:2017-08-26肺癌是我國非常常見的肺部腫瘤,不同的病理學分型及分期的肺癌患者,其治療方案也千差萬別。肺腺樣囊性癌是涎腺樣中腫瘤的一種,發(fā)病率極低,在臨床極為少見。木文收集了2012年1月-2016年12月間我院收診的4例肺腺樣囊性癌患者,通過對患者病理學分型,免疫組化檢查,表皮生長因子受體(epidermalgrowthfactorreceptor,EGFR)及間變性淋巴瘤激酶(anapl